BioSpace News Archive

Recently has unveiled a remarkable announcement: the inauguration of the Huahai Institute of Vitiligo Research in Shanghai.

AM-Pharma B.V. announced an updated clinical development strategy to evaluate ilofotase alfa in two indications.

Immunovant, Inc. announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor inhibitor.

Immunovant, Inc. announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor inhibitor.

IDEAYA Biosciences, Inc. announces that the U.S. FDA has granted Fast Track designation to IDEAYA’s development program investigating IDE161, a potent and selective inhibitor of poly glycohydrolase, for the treatment of adult patients having advanced or metastatic ovarian cancer with germline or somatic BRCA 1/2 mutations who are platinum resistant and have received prior antiangiogenic and poly polymerase inhibitor therapies.

Rockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and related neurodegenerative disorders, announced that the company will be presenting at upcoming industry and investor conferences.

Revvity, Inc., unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.

Drug Farm, a clinical-stage biopharmaceutical company, announced that it has dosed the first chronic hepatitis B patient in Part 3 of its Phase 1 clinical trial.

Moon Surgical, a French-American pioneer in collaborative robotics, announced that Baptist Health performed the first clinical procedures in the United States using the Maestro System.